Clustered nanobody-drug conjugates for targeted cancer therapy

被引：18

作者：

Wu, Tiantian ^{[1
]}

Liu, Manman ^{[1
]}

Huang, Hai ^{[1
]}

Sheng, Yaping ^{[1
]}

Xiao, Haihua ^{[2
]}

Liu, Yangzhong ^{[1
]}

机构：

[1] Univ Sci & Technol China, Affiliated Hosp USTC 1, Div Life Sci & Med, Dept Chem, Hefei 230001, Anhui, Peoples R China

[2] Chinese Acad Sci, Inst Chem, Beijing Natl Lab Mol Sci, State Key Lab Polymer Phys & Chem, Beijing 100190, Peoples R China

来源：

CHEMICAL COMMUNICATIONS | 2020年 / 56卷 / 65期

基金：

美国国家科学基金会; 国家重点研发计划;

关键词：

EGFR; PEGYLATION; DELIVERY; SITE;

D O I：

10.1039/d0cc03396k

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

A clustered Nb-drug conjugate (cNDC@PEG) was designed using anti-EGFR Nb to specifically deliver Pt(iv) prodrugs to tumors. cNDC@PEG efficiently targets EGFR positive tumor cells, and the clustered cNDC@PEG is more efficient in inhibiting tumor growthin vivothan the monomeric NDC. This work provides a novel strategy for the construction of a multi-valent NDC using dendrimers.

引用

页码：9344 / 9347

页数：4

共 50 条

[21] Bombesin-drug conjugates in targeted therapy for small cell lung cancer
Zhang, Yichi
Holland, Elizabeth
Dinh, Anna
Au, Duc
Sun, Lichun
AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12 (03): : 927 - 937
[22] Development of small molecule fluorescent dye drug conjugates in targeted cancer therapy
Mrdenovic, Stefan
AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL UROLOGY, 2021, 9 (04): : 261 - 263
[23] EGFR targeted nanobody-photosensitizer conjugates for photodynamic therapy in a pre-clinical model of head and neck cancer
van Driel, Pieter B. A. A.
Boonstra, Martin C.
Slooter, Maxime D.
Heukers, Raimond
Stammes, Marieke A.
Snoeks, Thomas J. A.
de Bruijn, Henriette S.
van Diest, Paul J.
Vahrmeijer, Alexander L.
Henegouwen, Paul M. P. van Bergen En
van de Velde, Cornelis J. H.
Lowik, ClemensW. G. M.
Robinson, Dominic J.
Oliveira, Sabrina
JOURNAL OF CONTROLLED RELEASE, 2016, 229 : 93 - 105
[24] Antibody-drug conjugates: targeted drug delivery for cancer
Alley, Stephen C.
Okeley, Nicole M.
Senter, Peter D.
CURRENT OPINION IN CHEMICAL BIOLOGY, 2010, 14 (04) : 529 - 537
[25] Innovative Design of Targeted Nanoparticles: Polymer-Drug Conjugates for Enhanced Cancer Therapy
Junyaprasert, Varaporn Buraphacheep
Thummarati, Parichart
PHARMACEUTICS, 2023, 15 (09)
[26] Antibody-Drug Conjugates: A Review on the Epitome of Targeted Anti-Cancer Therapy
Hasan, Mahmudul
Alam, Safaet
Poddar, Saikat Kumar
CURRENT CLINICAL PHARMACOLOGY, 2018, 13 (04): : 236 - 251
[27] Antibody-drug conjugates for targeted cancer therapy: Recent advances in potential payloads
Xi, Meiyang
Zhu, Jingjing
Zhang, Fengxia
Shen, Hualiang
Chen, Jianhui
Xiao, Ziyan
Huangfu, Yanping
Wu, Chunlei
Sun, Haopeng
Xia, Gang
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 276
[28] Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice
Xenaki, Katerina T.
Dorrestijn, Bram
Muns, Joey A.
Adamzek, Kevin
Doulkeridou, Sofia
Houthoff, HendrikJan
Oliveira, Sabrina
Henegouwen, Paul M. P. van Bergen en
THERANOSTICS, 2021, 11 (11): : 5525 - 5538
[29] Antibody Drug Conjugates for Cancer Therapy
Polakis, Paul
PHARMACOLOGICAL REVIEWS, 2016, 68 (01) : 3 - 19
[30] Trends in cancer-targeted antibody–drug conjugates
François-Clément Bidard
Olivier Trédan
Targeted Oncology, 2014, 9 : 1 - 8

← 1 2 3 4 5 →